ULTIBRO BREEZHALER 110/50  indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

ultibro breezhaler 110/50 indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); indacaterol maleate, quantity: 143 microgram (equivalent: indacaterol, qty 110 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - ultibro breezhaler 110/50 is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd), and for the reduction of exacerbations of copd in patients with a history of exacerbations.

MICRONELLE 30 ED levonorgestrel 150 microgram and ethinylestradiol 30 microgram film-coated tablet blister pack 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

micronelle 30 ed levonorgestrel 150 microgram and ethinylestradiol 30 microgram film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

DYLASTINE 125/50 azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

dylastine 125/50 azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle

viatris pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; azelastine hydrochloride, quantity: 137 microgram/actuation (equivalent: azelastine, qty 125 microgram/actuation) - spray, nasal - excipient ingredients: glycerol; disodium edetate; phenethyl alcohol; purified water; carmellose sodium; microcrystalline cellulose; polysorbate 80; benzalkonium chloride - symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate.

DYMISTA 125/50 azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

dymista 125/50 azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle

viatris pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; azelastine hydrochloride, quantity: 137 microgram/actuation (equivalent: azelastine, qty 125 microgram/actuation) - spray, nasal - excipient ingredients: disodium edetate; purified water; glycerol; microcrystalline cellulose; polysorbate 80; phenethyl alcohol; benzalkonium chloride; carmellose sodium - symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate.

FOSTAIR 100/6 beclometasone dipropionate 100 microgram and formoterol fumarate dihydrate 6 microgram  pressurised inhalation solution 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fostair 100/6 beclometasone dipropionate 100 microgram and formoterol fumarate dihydrate 6 microgram pressurised inhalation solution

chiesi australia pty ltd - beclometasone dipropionate, quantity: 100 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches). copd (fostair 100/6 only) symptomatic treatment of adults with severe copd (fev1 less than 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

MICROGESTIN FE- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit
MICROGESTIN- norethindrone acetate and eth 美国 - 英文 - NLM (National Library of Medicine)

microgestin fe- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit microgestin- norethindrone acetate and eth

physicians total care, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - microgestin ® 1/20, microgestin ® fe 1/20 , microgestin ® 1.5/30, and microgestin ® fe 1.5/30 are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease cerebral vascular or coronary artery dise

Bufomix Easyhalar 160 MICROGRAM, 4.5 MICROGRAM 约旦 - 英文 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

bufomix easyhalar 160 microgram, 4.5 microgram

شركة أدوية الحكمة - hikma pharmaceuticals - budesonide 160 microgram, formoterol fumarate dihydrate 4.5 microgram - 160 microgram, 4.5 microgram

Bufomix Easyhalar 160 MICROGRAM, 4.5 MICROGRAM 约旦 - 英文 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

bufomix easyhalar 160 microgram, 4.5 microgram

شركة أدوية الحكمة - hikma pharmaceuticals - budesonide 160 microgram, formoterol fumarate dihydrate 4.5 microgram - 160 microgram, 4.5 microgram

RYALTRIS olopatadine 600 microgram/actuation and mometasone furoate 25 microgram/actuation nasal spray bottle 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

ryaltris olopatadine 600 microgram/actuation and mometasone furoate 25 microgram/actuation nasal spray bottle

seqirus pty ltd - olopatadine hydrochloride, quantity: 665 microgram/actuation (equivalent: olopatadine, qty 600 microgram/actuation); mometasone furoate monohydrate, quantity: 25.86 microgram/actuation (equivalent: mometasone furoate, qty 25 microgram/actuation) - spray, nasal - excipient ingredients: sodium chloride; hydrochloric acid; carmellose sodium; sodium hydroxide; dibasic sodium phosphate heptahydrate; dispersible cellulose; benzalkonium chloride; water for injections; polysorbate 80; disodium edetate - ryaltris is indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 6 years of age and older.

AirFluSal MDI 25 microgram/125 microgram/dose pressurised inhalation, suspension 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

airflusal mdi 25 microgram/125 microgram/dose pressurised inhalation, suspension

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone